Your browser doesn't support javascript.
loading
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma.
Terao, Toshiki; Yamashita, Takeshi; Fukumoto, Ami; Kamura, Yuya; Ikeda, Daisuke; Kuzume, Ayumi; Tabata, Rikako; Tsushima, Takafumi; Miura, Daisuke; Narita, Kentaro; Takeuchi, Masami; Doi, Masahiro; Umezawa, Yuka; Otsuka, Yoshihito; Takamatsu, Hiroyuki; Matsue, Kosei.
Affiliation
  • Terao T; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Yamashita T; Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.
  • Fukumoto A; Division of Internal Medicine, Keiju Kanazawa Hospital, Ishikawa, Japan.
  • Kamura Y; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Ikeda D; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Kuzume A; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Tabata R; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Tsushima T; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Miura D; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Narita K; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Takeuchi M; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Doi M; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Umezawa Y; Department of Clinical Laboratory, Kameda Medical Center, Kamogawa, Japan.
  • Otsuka Y; Department of Clinical Laboratory, Kameda Medical Center, Kamogawa, Japan.
  • Takamatsu H; Department of Clinical Laboratory, Kameda Medical Center, Kamogawa, Japan.
  • Matsue K; Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan. takamaz@staff.kanazawa-u.ac.jp.
Int J Hematol ; 115(5): 737-747, 2022 May.
Article de En | MEDLINE | ID: mdl-35190963
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Vaccins / COVID-19 / Myélome multiple Type d'étude: Guideline / Observational_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Int J Hematol Sujet du journal: HEMATOLOGIA Année: 2022 Type de document: Article Pays d'affiliation: Japon Pays de publication: Japon
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Vaccins / COVID-19 / Myélome multiple Type d'étude: Guideline / Observational_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Int J Hematol Sujet du journal: HEMATOLOGIA Année: 2022 Type de document: Article Pays d'affiliation: Japon Pays de publication: Japon